The identification of inactivating mutations in two key components of the Hippo–YAP pathway, LATS1 and PTPN14 genes, provides clear evidence of the involvement of this signaling cascade in BCC, adding BCC to the broad group of human cancers with a deregulated Hippo–YAP axis. This evidence concerns the gene PTPN14 and cancer.